SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConvaTec Regulatory News (CTEC)

Share Price Information for ConvaTec (CTEC)

Share Price is delayed by 15 minutes
Get Live Data
202.60    2.60 (1.30%)
Bid:
203.20
Ask:
203.60
Spread: 0.40 (0.197%)
Market Cap: £3.96b
CTEC Live PriceLast checked at - London Stock Exchange

Intraday ConvaTec Share Chart

Proposed Placing in ConvaTec Group Plc

5 Jun 2017 16:53

RNS Number : 1903H
UBS Limited
05 June 2017
Β 

Press release, 5 June 2017

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER OF SECURITIES IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION.

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Nordic Capital and Avista announce the proposed placing of approximately 200 million ordinary shares in ConvaTec Group Plc

Nordic Capital and Avista (each as defined below) intend to sell approximately 200 million shares in aggregate in ConvaTec Group Plc ("ConvaTec") to institutional investors by way of an accelerated bookbuild (the "Proposed Placing").

Goldman Sachs International ("Goldman Sachs"), Merrill Lynch International ("BofA Merrill Lynch") and UBS Limited ("UBS") have been appointed as Joint Bookrunners of the Proposed Placing by Nordic Capital and Avista.

Nordic Capital and Avista currently own 314,158,828 shares (16.1%) and 137,244,619 shares (7.0%), respectively.

The final number of Placing Shares to be placed and the price at which the Placing Shares are to be placed will be agreed by the Joint Bookrunners and Nordic Capital and Avista at the close of the bookbuild process, and the result of the Proposed Placing will be announced as soon as practicable thereafter.

In connection with the Proposed Placing, Nordic Capital and Avista have agreed not to sell or distribute any ordinary shares in ConvaTec which are not sold in the Proposed Placing for a period of 90 days after completion of the Proposed Placing (subject to waiver by the Joint Bookrunners and certain customary exceptions, including any enforcement by the lenders under the terms of existing margin loans entered into by Nordic Capital and Avista). The Avista lock-up is subject to a carve out for a process of distribution in kind (or sale and distribution) of its residual holding from 29 June 2017, the date on which its lock-up from the previous placing, which completed on 31 March 2017, (the "March Placing") expires.

To permit the Proposed Placing, BofA Merrill Lynch, Goldman Sachs and UBS have waived the 90 day lock-up arrangement put in place at the time of the sale of shares to Novo A/S and the March Placing, which is due to expire on 29 June 2017, in respect of the shares sold in the Proposed Placing.

ConvaTec will not receive any proceeds from the Proposed Placing.

Enquiries

BofA Merrill Lynch +44 20 7995 3700

Neil Kell

James Fleming

Andrew Briscoe

Β 

Goldman Sachs +44 20 7774 1000

Richard Cormack

William Smiley

Soren Moller-Rasmussen

Β 

UBS +44 20 7567 8000

Jasper Tans

Christopher Smith

Gareth McCartney

Β 

Nordic Capital +46 8 440 50 50

Katarina Janerud, NC Advisory AB, advisor to the Nordic Capital Funds

Β 

Avista +1 212 521 4879

Daniel Yunger, KEKST

Β 

Β 

"Nordic Capital" refers to Nordic Capital VII Limited, acting in its capacity as General Partner of Nordic Capital VII Alpha, L.P. and Nordic Capital VII Beta, L.P. together with associated co-investment vehicles and Nordic Capital VI Limited, acting in its capacity as General Partner of Nordic Capital VI Alpha, L.P. and Nordic Capital VI Beta, L.P. together with associated co-investment vehicles.

Β 

"Avista" is the limited liability companies and limited partnerships managed by Avista Capital Managing Member, LLC with interests in ConvaTec, including Avista Capital Partners LP, Avista Capital Partners II LP and their affiliated funds and co-invest vehicles.

IMPORTANT NOTICE

This announcement is not for publication or distribution or release, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Canada, Australia or Japan or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No action has been taken that would permit an offering of the Placing Shares or possession or distribution of this announcement in any jurisdiction where action for that purpose is required.

This announcement does not constitute or form part of an offer for sale or solicitation of an offer to purchase or subscribe for securities in the United States, Canada, Australia, Japan or any other jurisdiction where such offer or solicitation would be unlawful. The Placing Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold, directly or indirectly, in the United States, absent registration under or pursuant to an exemption from, or transaction not subject to, the registration requirements of, the Securities Act. No public offering of securities is being made in the United States or in any other jurisdiction.

In member states of the European Economic Area ("EEA") which have implemented the Prospectus Directive (each, a "Relevant Member State"), this announcement and any offer of Placing Shares if made subsequently is directed exclusively at persons who are "qualified investors" within the meaning of the Prospectus Directive ("Qualified Investors"). For these purposes, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in a Relevant Member State), and includes any relevant implementing measure in the Relevant Member State. In the United Kingdom this announcement is directed exclusively at, and any investment or investment activity to which this announcement relates is available only to, and will be engaged in only with, Qualified Investors who are (i) investment professionals falling with Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) other persons to whom an offer of the Placing Shares may otherwise be lawfully communicated (all such persons together being referred to as "relevant persons"). Persons in the United Kingdom who are not relevant persons and persons in other Relevant Member States who are not Qualified Investors should not take any action on the basis of this announcement and should not act or rely on it.

No prospectus or offering document has been or will be prepared in connection with the Proposed Placing. Any investment decision in connection with the Proposed Placing must be made on the basis of all publicly available information relating to ConvaTec and ConvaTec's shares. Such information has not been independently verified. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

No representation or warranty, express or implied, is made by any of BofA Merrill Lynch, Goldman Sachs or UBS or any of their respective affiliates as to the accuracy, completeness, verification or sufficiency of the information set out in this announcement or such publicly available information, and nothing in this announcement will be relied upon as a promise or representation in this respect, whether or not to the past or future, and accordingly none of BofA Merrill Lynch, Goldman Sachs or UBS or any of their respective affiliates or any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

In connection with the Proposed Placing, BofA Merrill Lynch, Goldman Sachs and UBS or any of their respective affiliates acting as an investor for its own account may take up as a portion of the Placing Shares as a principal position and in that capacity may retain, purchase, sell, offer to sell for its own account such Placing Shares and other securities of ConvaTec or related investments in connection with the Proposed Placing or otherwise. In addition, BofA Merrill Lynch, Goldman Sachs and UBS or any of their respective affiliates may enter into financing arrangements (including swaps and contracts for differences) with investors in connection with which BofA Merrill Lynch, Goldman Sachs and UBS (or any of their respective affiliates) may from time to time acquire, hold or dispose of Placing Shares. Accordingly, references to the shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by, BofA Merrill Lynch, Goldman Sachs, UBS and any of their respective affiliates acting as investors for their own accounts. BofA Merrill Lynch, Goldman Sachs and UBS do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

This announcement does not purport to identify or suggest the risks (direct or indirect) which may be associated with an investment in ConvaTec or ConvaTec's shares.

Each of BofA Merrill Lynch, Goldman Sachs, and UBS, which are authorised by the Prudential Regulatory Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, are acting on behalf of the Sellers only in connection with the Proposed Placing and no one else, and will not be responsible to anyone other than the Sellers for providing the protections offered to clients of BofA Merrill Lynch, Goldman Sachs and UBS nor for providing advice in relation to the Placing Shares or the Proposed Placing.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCEASKSESEXEFF
Date   Source Headline
28th May 202611:00 amRNSHolding(s) in Company
27th May 202611:00 amRNSDirector/PDMR Shareholding
26th May 202611:00 amRNSHolding(s) in Company
21st May 20263:30 pmRNSResults of AGM
21st May 20267:00 amRNSAGM trading update for four months ended 30 April
13th Apr 202612:00 pmRNSProfessor Constantin Coussios steps down
9th Apr 20267:00 amRNSCapital Markets Day
17th Mar 20261:00 pmRNSNotice of AGM
17th Mar 202611:00 amRNSDirector/PDMR Shareholding
12th Mar 20262:30 pmRNSDirector/PDMR Shareholding
10th Mar 20261:00 pmRNSPublication of Annual Report
24th Feb 20267:00 amRNSConvatec FY25 Results
6th Feb 202611:00 amRNSHolding(s) in Company
2nd Jan 202611:00 amRNSTotal Voting Rights
19th Dec 202512:00 pmRNSHolding(s) in Company
19th Dec 202512:00 pmRNSHolding(s) in Company
17th Dec 20253:00 pmRNSHolding(s) in Company
10th Dec 20253:00 pmRNSHolding(s) in Company
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 202512:00 pmRNSHolding(s) in Company
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 202511:00 amRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 202511:00 amRNSHolding(s) in Company
25th Nov 20257:00 amRNSTransaction in Own Shares
24th Nov 20255:05 pmRNSHolding(s) in Company
24th Nov 20255:00 pmRNSHolding(s) in Company
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20255:30 pmRNSHolding(s) in Company
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20251:30 pmRNSHolding(s) in Company
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20256:00 pmRNSConvaTec Group
18th Nov 20257:00 amRNSPRICED SECONDARY OFFERING IN CONVATEC GROUP PLC
17th Nov 20254:57 pmRNSPROPOSED SECONDARY OFFERING IN CONVATEC GROUP PLC
14th Nov 20253:00 pmRNSHolding(s) in Company
13th Nov 20257:05 amRNSTransaction in Own Shares
13th Nov 20257:00 amRNSTrading update for 10 months ended 31 October 2025
12th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20257:00 amRNSTransaction in Own Shares
10th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:05 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSCEO and CFO appointments
5th Nov 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.